D
Dina B. Tresnan
Researcher at Pfizer
Publications - 9
Citations - 11158
Dina B. Tresnan is an academic researcher from Pfizer. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 5 publications receiving 4463 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David K. C. Cooper,Timothy Jennings,Donald M Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of.
Posted ContentDOI
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas,Edson D. Moreira,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Fernando P. Polack,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Xia Xu,Satrajit Roychoudhury,Kenneth Koury,Salim Bouguermouh,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Qi Yang,Paul A. Liberator,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, 44,165 ≥16-year-old participants and 2,264 12-15-year old participants were randomized to receive 2 doses, 21 days apart, of 30 µg BNT162b2 or placebo as mentioned in this paper.
Journal ArticleDOI
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Edson D. Moreira,Nicholas Kitchin,Xia Xu,Samuel S. Dychter,Stephen Lockhart,Alejandra Gurtman,John L. Perez,Cristiano A. F. Zerbini,Michael E Dever,Timothy W Jennings,Donald Brandon,Kevin D Cannon,Michael J. Koren,Douglas S Denham,Mezgebe Berhe,David Fitz-Patrick,Laura L. Hammitt,Nicola P. Klein,Haylene Nell,Georgina Keep,Xingbin Wang,Kenneth Koury,Kena A. Swanson,David A. Cooper,Claire M. Lu,Özlem Türeci,Eleni Lagkadinou,Dina B. Tresnan,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the Pfizer–BioNTech vaccine during a median follow-up of 2.5 months.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Stephen J. Thomas,Edson D. Moreira,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Fernando P. Polack,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Xia Xu,Satrajit Roychoudhury,Kenneth Koury,Salim Bouguermouh,Warren Kalina,David K. C. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Qi Yang,Paul A. Liberator,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: In this paper, BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored full-length spike protein.